已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Retrospective registry of patients with locally advanced/metastatic HR+/HER2− breast cancer treated in clinical practice in Andalusia

医学 帕博西利布 转移性乳腺癌 内科学 肿瘤科 乳腺癌 癌症
作者
Natalia Chavarría Piudo,Isabel Blancas,Encarnación González Flores,Fernando Henao Carrasco,Pilar López Álvarez,David Morales Pancorbo,Salvador Gámez Casado,María de la Cabeza Lomas Garrido,José Manuel Rodríguez García,Antonia Martínez Guisado,Adrian Sánchez Vega,Manuel Ruíz-Borrego
出处
期刊:Clinical & Translational Oncology [Springer Science+Business Media]
标识
DOI:10.1007/s12094-024-03510-8
摘要

Abstract Background Limited data are available regarding the real-world effectiveness and safety of Cyclin Dependent Kinase 4/6 inhibitor (CDK4/6i) (palbociclib/ribociclib) just as a first-line treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2‒) metastatic breast cancer (MBC). Objective To assess whether clinical or demographic characteristics limit access to first-line CDK4/6i treatment in clinical practice in the Autonomous Community of Andalusia (Spain) between November 2017 and April 2020. In addition, effectiveness will be described in an exploratory analysis. Methods Physicians from 12 centers participated in selecting demographic and clinical characteristics, treatment, and outcome data from women with HR + /HER2- MBC treated with or without CDK4/6i in addition to hormonal in the first-line setting, in a 3:1 proportion. Kaplan–Meier analysis estimated progression-free rates (PFRs) and survival rates (SRs). Results A total of 212 patients were included, of whom 175 (82.5%) were in the CDK4/6i treatment group and 37 (17.5%) were in the non-CDK4/6i treatment group (control group). Patients in the CDK 4/6i treatment group were younger (p = 0.0011), the biopsies of the metastatic site at the moment of the relapse were most commonly performed (p = 0.0454), and had multiple metastatic sites (p = 0.0025). The clinical benefit rate (CBR) was 82.3% in the CDK4/6i group and 67.8% in the control group. Median time to a progression event or death (PFS) was 20.4 months (95%CI 15.6–28) in the CDK4/6i group and 12.1 months (95%CI 7.9–not reached) in the control group. Conclusions Younger patients, biopsies of metastatic disease and with multiple metastatic sites were more frequently treated with CDK4/6i in our daily clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
细心采萱关注了科研通微信公众号
1秒前
1秒前
小白完成签到,获得积分10
1秒前
Glowing发布了新的文献求助10
2秒前
tanjing0912发布了新的文献求助10
2秒前
善学以致用应助乐观囧采纳,获得10
4秒前
4秒前
一二宝发布了新的文献求助10
5秒前
5秒前
6秒前
7秒前
ovoclive完成签到,获得积分10
8秒前
lxgz发布了新的文献求助10
8秒前
leon111发布了新的文献求助10
10秒前
贺贺完成签到,获得积分10
10秒前
10秒前
空林饮溪完成签到 ,获得积分10
11秒前
浅音应助程依婷采纳,获得10
11秒前
烟花应助十分十分佳采纳,获得10
11秒前
Jing完成签到,获得积分10
13秒前
沦落而完成签到,获得积分10
14秒前
浮游应助橘涂采纳,获得10
14秒前
科研通AI6应助铮铮铁骨采纳,获得10
14秒前
Lydia发布了新的文献求助10
15秒前
16秒前
18秒前
义气的安白完成签到,获得积分10
18秒前
18秒前
爆米花应助王艺霖采纳,获得10
18秒前
禾苗发布了新的文献求助10
19秒前
20秒前
20秒前
luwenbin发布了新的文献求助10
21秒前
汉堡包应助务实的犀牛采纳,获得10
21秒前
张轩完成签到,获得积分10
21秒前
温存完成签到,获得积分10
22秒前
牛蛙丶丶发布了新的文献求助10
22秒前
23秒前
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Zeolites: From Fundamentals to Emerging Applications 1500
Encyclopedia of Materials: Plastics and Polymers 1000
Architectural Corrosion and Critical Infrastructure 1000
Early Devonian echinoderms from Victoria (Rhombifera, Blastoidea and Ophiocistioidea) 1000
Hidden Generalizations Phonological Opacity in Optimality Theory 1000
Handbook of Social and Emotional Learning, Second Edition 900
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4924963
求助须知:如何正确求助?哪些是违规求助? 4195117
关于积分的说明 13030291
捐赠科研通 3966853
什么是DOI,文献DOI怎么找? 2174302
邀请新用户注册赠送积分活动 1191684
关于科研通互助平台的介绍 1101172